Bone marrow transplant recipients may carry an increased risk of bone diseases, involving numerous factors that affect bone mineral metabolism. Interleukin-6 is a potent stimulator of bone resorption in vivo. The soluble fraction of interleukin-6 receptor is reported to trigger osteoclast formation by interleukin-6 in vitro.
Introduction
Following bone marrow transplantation, plasma in-_, . · · * ± -j · ι terleukin-6 levels are regularly raised in febrile episodes Bone marrow transplant recipients are at increased risk · j · i. i_ · j · * j -., ,. ,.. _, . ,. chronic graft-versus-host reaction (4) . Several studies m vitro (5, 6) and in vivo (7, 8, 9) have shown that in-(a) Sex hormone deficiency increases bone loss, espe-terleukin-6 is a potent stimulator of bone resorption. Incially in women following pretransplant conditioning terleukin-6 exerts its activity via a cell surface receptor with total body irradiation or chemotherapy; which consists of two components: a ligand-binding M T /u\ η ^ ·Λ Λ-* + -u A 80000 glycoprotein chain (interleukin-6 receptor) and (b) Glucocorticoids predispose to osteopema by de-,.
.ί · "· , · , ^ . , / ΛΛΛΛ u r . .. Λ .
u a non-ligand binding but signal-transducing M r 130000 pressing bone formation and increasing bone resorpt 6 . , . ? , " * , . , , , . . glycoprotein chain (gp!30). It has been shown that the soluble fraction of interleukin-6 receptor which lacks (c) Cyclosporin A is known to produce high bone re-transmembrane and cytoplasmic regions can also medimodelling with bone resorption exceeding bone forma-ate the interleukin-6 signal through gp!30 (5). The solution and can therefore induce osteopenia when applied ble fraction of interleukin-6 receptor is reported to trigin immunosuppressive doses.
ger osteoclast formation by interleukin-6 in vitro (5).
Reduced bone mineral density in patients following In the present study bone turnover in patients following bone marrow transplantation has already been shown bone marrow transplantation was assessed by measuring (2) . serum mass concentrations of bone alkaline phosphatase (EC 3.1,3.1) (a marker of bone formation) and the urinary excretion of pyridinium cross-links (a marker of bone resorption). ' The resulting values were compared with the plasma levels of interleukin-6 and the soluble fraction of its receptor.
Patients and Methods

Patients
We examined 177 blood and 44 urine samples from 21 patients after bone marrow transplantation (age: 36.1 ± 2.0 years) (mean ± SEM) (13 males, 8 females) (8 chronic granulocyte leukaemia, 4 acute non-lymphoblastic leukaemia, 5 'high-grade' non-Hodgkin y s lymphoma, 1 Hodgkin's lymphoma, 1 acute lymphoblastic leukaemia, 1 refractory anaemia and 1 multiple myeloma). Eighteen patients received allogeneic bone marrow transplantation whereas three patients received autologous bone marrow transplantation. The mean time since transplantation was 281 ±16 days (mean ± SEM). The number of blood/urine samples obtained from each patient ranged from 3 to 29 (mean: 9).
Conditioning regimens
Seventeen patients received pretransplant conditioning with total body irradiation (2 Gy X 6 or 2.5 Gy X 4) and 'high-dose' cyclophosphamide (120-180 mg/kg -d). In four patients cyclophosphamide was given alone. Furthermore, etoposide (VP-16) 10-25 mg/ kg · d X 2 was given in 10 patients and 1.3-bis(2-chloroethyl)-lnitrosourea 5 mg/kg · d in 4 patients.
Graft-versus-host disease prophylaxis and therapy
To prevent graft-versus-host disease, patients undergoing allogeneic bone marrow transplantation received cyclosporin A (4 mg/ kg · d i. v. for 35 ±3 days, then 12 mg/kg · d p.o. for 271 ± 21 days) (mean ± SEM) and 'short-term' methotrexate (15 mg/m 2 at day 1 and 10 mg/m 2 at days 3 and 6 after bone marrow transplantation). Cyclosporin A concentrations in whole blood were 200-300 μg/l in the first six months after bone marrow transplantation. Five of the patients received prednisolone 1 -1.5 mg/kg · d p. o.
All female patients following bone marrow transplantation had clinical and biochemical evidence of primary ovarian failure. None of the patients had clinical or biochemical signs of disturbed vitamin D or phosphate metabolism. Moreover, none of the patients had had any bone disease before transplantation [bone density measurements (using dual-energy X-ray absorptiometry) performed before transplantation yielded values within the reference range both at the lumbar spines as well as at the femoral neck (as compared with sex-and age-adjusted controls)].
Methods
Bone alkaline phosphatase mass concentration in serum was determined by an immunoradiometric assay (Tandem®-R Ostase™; Hybritech Inc., San Diego, CA [U. S. A.]; no. 3040 BE) employing two monoclonal antibodies against two different epitopes of the bone alkaline phosphatase molecule. A calibration curve was constructed by linear interpolation between the plotted analytical results. The following reference intervals (mean ± 2 X SD) for bone alkaline phosphatase concentrations in serum were established in apparently healthy persons: (1) 3.2-15.8 μg/l (males, n = 38) (2) 2.3-12.2 μg/l (females, n = 47). Age-range was 27-51 years (males) and 19-48 years (females). Bone alkaline phosphatase values were higher in males than in females (p < 0.0001).
The urinary excretion of pyridinium cross-links was determined by a competitive enzyme immunoassay (Collagen Crosslinks™ Kit; Metra Biosystems Inc.; Palo Alto, CA [U. S. A.]) employing a polyclonal antibody against pyridinoline which shows 100% cross-reactivity with deoxypyridinoline. A curve was constructed employing a 4-parameter curve fitting equation. The following reference interval (mean ± 2 X SD) for the urinary excretion of pyridinium cross-links in second morning urine samples was established in apparently healthy persons (the samples were obtained between 8.00 and 10.00 a.m.): pyridinoline equivalents, 12-73 μπιοΐ/πιοί creatinine (n = 75; 33 males and 42 females; age-range: 20-56 years). There was no dependence of reference values upon sex.
Plasma levels of interleukin-6 were determined with an enzyme immunoassay (Quantikine™ HS Human-IiL-6 Immunoassay; R& D Systems; Minneapolis, MN [U. S. A.]). The upper reference limit (mean H-2 X SD; n = 23; 17 males and 6 females) was 2.4 ng/1.
The soluble plasma fraction of interleukin-6 receptor was determined with an enzyme immunoassay (Quantikine™ Human IL-6 sR Immunoassay; R&D Systems; Minneapolis, MN [U.S.A.]). The reference interval (mean ± 2 X SD; n = 23; 17 males and 6 females) was 9.7-67.4 μg/l.
The potassium salt of ethylenediaminetetraacetic acid was used as anticoagulant in the latter two tests.
Statistical analysis
The statistical methods employed included the U-test according to Mlcoxon, Mann & Wlutney (two-tailed) for unpaired samples and linear correlation coefficients (10) . Multiple regression analysis was performed with SPSS/PC+ V2.0 employing the procedure REGRESSION with a 'stepwise' selection of the independent variables.
Results
Comparison of mean values obtained from each patient revealed that following bone marrow transplantation, fem ale -but not male -patients showed higher serum bone alkaline phosphatase values than age-and sex-adjusted controls (p < 0.05). After bone marrow transplant tation both female and male patients showed a higher urinary excretion of pyridinium cross-links than apparently healthy persons (p < 0.05). There was a lack of correlation between serum bone alkaline phosphatase values and the urinary excretion of pyridinium crosslinks (p = 0.562) (tab. 1 and fig. la,b) . No correlation was observed between the values of these two biochemi- * p < 0.05 *** p < 0.001 ; cal markers of bone metabolism (measured after transplantation) and bone mineral density (at lumbar spines or femoral neck) (obtained before transplantation) (p > 0.05).
Following bone marrow transplantation there was a marked increase of interleukin-6 plasma levels (p < 0.001) but no significant difference in the soluble plasma fraction of its receptor between patients and apparently healthy persons (p = 0.838). Both in apparently healthy persons as well as in patients following bone marrow transplantation there was a lack of correlation between plasma interleukin-6 concentrations and the soluble plasma fraction of its receptor (p > 0.5) (tab. 1 and fig. Ic, d ).
There was no correlation between the values of pyridinium cross-links excretion, plasma interleukin-6 and plasma soluble interleukin-6 receptor levels on the one hand and time after transplantation on the other (p > 0.05), whereas a significant increase of serum bone alkaline phosphatase was observed within the first year after transplantation (p < 0.01).
Bivariate analysis showed a significant correlation between the urinary excretion of pyridinium cross-links and plasma interleukin-6 concentrations (tab. 2). To assess other possible influences upon the urinary excretion of pyridinium cross-links, the relative effects of the following independent variables were determined by multiple regression analysis:
Tab. 2 Correlation coefficients between biochemical markers of bone metabolism and plasma cytokine levels in patients after bone marrow transplantation.
Analytes
Correlation coefficients The plasma concentration of interleukin-6 was the only independent predictor of the urinary excretion of pyridinium cross-links (p < 0.05) (tab. 3).
Discussion
In female, but not in male patients, there was a significant increase in the serum bone alkaline phosphatase values as compared with age-and sex-matched controls. This may be explained by the influence of primary ovarian failure following total body irradiation, whereas in men only a moderate elevation of gonadotropins and testosterone within the reference interval were observed (2, 11) . Cyclosporirji A may enhance the deleterious effect of oestrogen deficiency, since in oophorectomised rats bone mass loss is accelerated by the application of cyclosporin A (12).
Carlson et al. (13) found a depression of bone formation within the first three months following bone marrow transplantation, which is probably due to (a) an inhibitory effect of glucocorticosteroids upon bone formation, (b) damage of osteoprogenitor cells by the myeloablative therapy and (c) inhibition of osteoblast function by locally secreted cytokines. However, the follow-up period of this study was only 3 months after bone marrow transplantation, whereas in the present communication the mean time since transplantation was 281 days.
Reduced bone mineral density is a common finding in patients following liver, cardiac and bone marrow transplantation (2, 14, 15, 16) . This is in concordance with our findings of increased values of both bone formation and bone resorption, indicating increased bone turnover. Interestingly no correlation was found between bone alkaline phosphatase mass concentrations in serum and the urinary excretion of pyridinium cross-links. This is in contrast to previous findings of our group, as well as others, in patients with primary (17) or secondary (18) hyperparathyroidism and bone metaStases (19, 20) , indicating that in patients after bone marrow transplantation different influencing factors may affect bone formation and resorption, respectively.
A multivariate statistical approach revealed the plasma concentration of interleukin-6 as an independent predictor of the urinary excretion values of pyridinium crosslinks, whereas there is no augmenting effect of the soluble interleukin-6 receptor upon bone metabolism in patients undergoing bone marrow transplantation. In contrast, Tamura et al. (5) found that only simultaneous treatment with interleukin-6 and soluble interleukin-6 receptor induces formation of osteoclast4ike cells in vitro.
Several authors have observed that interleukin-6 enhances bone resorption in vivo:
(a) Inoculation of nude mice with Chinese hamster ovarian cells, which have been transfected with the murine interleukin-6 gene, induces hypercalcaemia (7); (b) Neutralising antibodies directed against interleukin-6 reverse hypercalcaemia associated with a human carcinoma cell line transplanted in nude mice (8);
(c) In oophorectomised rats, increased osteoclast development is mediated by interleukin-6 (9).
Recently, Khosla et al. (21) found that postmenopausal women did not show higher plasma interleukin-6 levels as compared with premenopausal women. However, the interleukin-lo/interleukin-1 receptor antagonist concentration ratio was significantly increased in postmenopausal women (21) , suggesting a possible effect of cytokines upon bone metabolism in postmenopausal women.
In conclusion, our findings suggest two variables possibly acting on bone metabolism in patients after bone marrow transplantation:
(1) Increase of bone formation in female -but not male -patients, possibly reflecting primary ovarian failure;
(2) Enhancement of bone resorption possibly mediated by circulating interleukin-6. However, it is admitted that numerous factors can affect bone mineral metabolism in patients undergoing organ transplantation (e. g., longterm parenteral nutrition, disturbances of vitamin D and phosphate metabolism, action of drugs) which may be difficult to differentiate in cross-sectionally designed clinical studies (1).
